Jose Baselga MD, PhD

Dr. Jose Baselga, MD, PhD, is a researcher and clinician focusing primarily on breast cancer. His laboratory focuses on mechanisms that limit the sensitivity to targeted therapy in solid tumors, in particular to PI3K/Akt/mTOR inhibitors and anti-HER2 agents. He has also been involved in the development of several molecularly targeted agents including trastuzumab (Herceptin) and lapatinib (Tykerb).
Dr. Baselga is currently the Physician-in-Chief of Memorial Sloan Kettering Cancer Center and has also been named as AACR President-Elect for 2014-2015. He has received a number of awards including a Young Investigator Award (1992) and a Career Development Award (1994) from ASCO, Elected Member of the American Society of Clinical Investigation (2004), AACR-Rosenthal Family Foundation Award (2008), and King James I Award (2008). In October 2014 he was elected to the Institute of Medicine. He has published over 300 peer-reviewed articles and is the founding editor of Cancer Discovery.
Dr. Baselga received his MD degree from the Universidad Autonoma of Barcelona in 1982. From 1996 to 2010, he was the Chairman of the Medical Oncology Service and Founding Director of the Vall d’Hebron Institute of Oncology (VHIO) at the Vall d'Hebron University Hospital in Barcelona. From 2010 to 2012, he was the chief of the Division of Hematology/Oncology and associate director of the Massachusetts General Hospital Cancer Center.